Sartorius Aktiengesellschaft/€SRT

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Sartorius Aktiengesellschaft

Sartorius Aktiengesellschaft is a German company engaged in the development, manufacturing, and distribution of laboratory equipment and bioprocess solutions. The company's core business is centered around two main segments: Bioprocess Solutions, which includes products for the production of biopharmaceuticals, such as filters, bags, and bioreactors, and Lab Products & Services, offering laboratory instruments like balances and pipettes for various research applications. Founded in 1870, Sartorius is headquartered in Göttingen, Germany, and maintains a global presence with operations in Europe, Asia, and the Americas. Its strategic positioning is reinforced by a strong focus on innovation and comprehensive product offerings catering to the biopharmaceutical industry. Competitive strengths include robust R&D capabilities and a well-integrated supply chain that supports rapid adaptation to industry demands. Sources: Sartorius Corporate Website, Annual Reports.

Ticker

€SRT
Sector

Primary listing

XETRA

Employees

13,685

SRT Metrics

BasicAdvanced
€12B
-
-
1.24
€0.73
0.46%

Bulls say / Bears say

Sartorius posted underlying EBITDA of €263 million in Q1 2025, up 12.2%, with its EBITDA margin up to 29.8%, showing strong operating leverage and profitability improvements. (Reuters)
The Group’s Q1 2025 order intake stayed solid, with a book-to-bill ratio well above 1, pointing to sustained demand across its business segments. (Reuters)
In Q4 2024, Bioprocess Solutions orders soared 23.1% to €856.7 million, topping J.P. Morgan estimates by 22%, highlighting strong end-market demand. (Reuters)
Lab Products & Services sales fell 4.8% in constant currencies in H1 2025, and underlying EBITDA margin narrowed to 22.3% from 23.6% a year earlier, signaling ongoing weakness in the lab division. (FT)
Equipment and systems sales in the Bioprocess Solutions segment stayed soft as customers remained reluctant to invest in capital-intensive solutions, offsetting consumables growth. (FT)
Despite beating preliminary results, Sartorius projects 2025 growth below its long-term average, reflecting a cautious outlook as the company manages a recovery in the still-volatile life sciences market. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €SRT

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs